Optiver Holding B.V. Acquires 158,041 Shares of Tilray Brands, Inc. $TLRY

Optiver Holding B.V. grew its holdings in Tilray Brands, Inc. (NASDAQ:TLRY) by 239.4% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 224,049 shares of the company’s stock after acquiring an additional 158,041 shares during the period. Optiver Holding B.V.’s holdings in Tilray Brands were worth $388,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Silverlake Wealth Management LLC acquired a new stake in shares of Tilray Brands in the 3rd quarter valued at $25,000. Oppenheimer & Co. Inc. bought a new position in Tilray Brands during the third quarter valued at about $25,000. Unified Investment Management acquired a new stake in shares of Tilray Brands in the third quarter worth about $26,000. J.W. Cole Advisors Inc. boosted its stake in shares of Tilray Brands by 203.2% during the 2nd quarter. J.W. Cole Advisors Inc. now owns 71,890 shares of the company’s stock worth $30,000 after acquiring an additional 48,177 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Tilray Brands during the 3rd quarter worth about $30,000. Institutional investors and hedge funds own 9.35% of the company’s stock.

Tilray Brands Stock Performance

TLRY opened at $7.99 on Friday. The stock’s 50 day simple moving average is $8.64 and its 200-day simple moving average is $11.09. The company has a current ratio of 2.81, a quick ratio of 1.72 and a debt-to-equity ratio of 0.19. The stock has a market cap of $930.91 million, a PE ratio of -0.36 and a beta of 2.02. Tilray Brands, Inc. has a 1 year low of $3.51 and a 1 year high of $23.20.

Tilray Brands (NASDAQ:TLRY) last posted its quarterly earnings results on Thursday, January 8th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.27). The business had revenue of $217.51 million for the quarter, compared to analyst estimates of $211.15 million. Tilray Brands had a negative return on equity of 6.35% and a negative net margin of 251.69%.During the same quarter in the prior year, the firm earned ($0.03) EPS. Sell-side analysts forecast that Tilray Brands, Inc. will post -0.2 EPS for the current year.

Analyst Ratings Changes

Several research firms recently weighed in on TLRY. Wall Street Zen upgraded Tilray Brands from a “sell” rating to a “hold” rating in a report on Sunday, February 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Tilray Brands in a research report on Wednesday, January 21st. Zacks Research upgraded shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 11th. ATB Cormark Capital Markets upgraded shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a research note on Wednesday, December 10th. Finally, Roth Mkm dropped their target price on shares of Tilray Brands from $20.00 to $10.00 and set a “neutral” rating on the stock in a report on Tuesday, January 20th. One research analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $13.33.

About Tilray Brands

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.